Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· December 9, 2025

Stock market today: Dow and S&P 500 slip, Nasdaq rises as Fed meeting kicks off, JOLTS data shows openings rose

View original at finance.yahoo.com
Stock market today: Dow and S&P 500 slip, Nasdaq rises as Fed meeting kicks off, JOLTS data shows openings rose US stocks were mixed on Tuesday as the Federal Reserve's December policy meeting kicked off and federal data showed job openings unexpectedly ticked higher even as layoffs jumped…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Trump would be looking for a new Fed chair to immediately move to cut rates

    80% confidence

  • Exxon expects to hit new earnings and cash flow targets with no increase in capital while generating 17% return on capital employed

    80% confidence

  • Exxon is ahead of its 2030 emissions reduction plans

    80% confidence

  • OPEC can't really afford a $40 or $30 barrel outcome because capital for many member countries is not as loose as in the 2010s

    80% confidence

  • It would be irresponsible to set out Fed rate cut plans for the next six months

    80% confidence

  • Consumers remain intentional in their shopping behaviors with at-home-cooking trends continuing to benefit our brands within our Meals & Beverages portfolio that deliver quality, convenience and value

    80% confidence

  • We believe affordability concerns are pushing the housing market towards equilibrium as home prices are trending towards flat

    80% confidence

  • 55% of US homes are now 40+ years old and will require higher levels of maintenance, repair and renovations in the near future

    80% confidence

  • Several years ago when we began to transform this company, we did so with one objective: to fully unlock our competitive advantages. Today, our transformation is driving industry-leading results

    80% confidence

  • While our Snacks business continues to weather category softness, our brands remain highly relevant

    80% confidence

  • Tesla unsupervised FSD milestone is very close

    80% confidence

  • Affordability concerns and general uncertainty have led consumers to stay put in their homes

    80% confidence

  • We're observing several dynamics that are pressuring housing and unproven demand. First, the elevated interest rate and mortgage rate environment since 2020 has stifled housing turnover as a result of the mortgage lobby effect

    80% confidence

  • Trump's farm bailout would not be possible without tariffs

    80% confidence

  • Housing market experiencing soft demand and choppy conditions this year, though luxury business remains differentiated

    80% confidence

  • Americans' affordability concerns are a con job

    80% confidence

  • Pent-up demand from consumers putting off larger projects can be greater than $20 billion and at some point will be a significant tail

    80% confidence

  • Costs at JPMorgan would rise in 2026 amid competition in credit card space and as AI investments drive higher spending

    80% confidence

  • Housing turnover has remained at historical lows since 2023, which has significantly reduced demand for projects associated with buying and selling money

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com